



INVESTOR PRESENTATION

MARCH 27, 2024



FORWARD-LOOKING STATEMENTS



This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “strategy,” “objective,” “designed,” “suggest,” “currently,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

- The rate and degree of market acceptance of Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel
- Evofem’s ability to successfully commercialize Phexxi in the United States and to enter into successful partnerships to commercialize Phexxi outside of the United States
- Evofem’s estimates regarding expenses, revenues, financial performance and capital requirements, including the length of time its capital resources will sustain its operations, and its ability to raise additional capital to fund its operations when/if needed
- Evofem’s ability to continue as a going concern
- Evofem’s ability to comply with the provisions and requirements of its debt arrangements and to pay amounts owed pursuant to its debt arrangements
- Evofem’s ability to retain members of its management and other key personnel and to expand its organization to accommodate potential growth
- Evofem’s ability to maintain and protect its intellectual property position and its ability to obtain additional patent protection for its product for current and investigational indications
- The potential for changes to current regulatory mandates requiring payers to cover FDA-approved or -cleared contraceptives without cost sharing
- Evofem’s ability to obtain or maintain third-party payer coverage and adequate reimbursement, and its reliance on the willingness of patients to pay out-of-pocket for Phexxi absent full or partial third-party payer reimbursement
- Evofem’s reliance on third-party providers and licensors, such as third-party manufacturers
- The presence or absence of any adverse events or side effects relating to the use of Phexxi, and,
- Any other risk factors detailed in Evofem’s filings from time to time with the U.S. Securities and Exchange Commission including, without limitation, the 10-K for the year ended December 31, 2022, filed with the SEC on March 27, 2024, and any subsequent filings.

The forward looking statements in this presentation represent Evofem’s views only as of the date of this presentation, March 27, 2024, and Evofem expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evofem’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this presentation are qualified in their entirety by this cautionary statement. This presentation also discusses estimates and other statistical data made by independent parties and by Evofem relating to market size and growth and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.




43.3M POTENTIAL PHEXXI USERS IN THE U.S.¹



(lactic acid, citric acid, and potassium bitartrate) Vaginal Gel
1.8%, 1%, 0.4%

U.S. MARKET BY CONTRACEPTIVE METHOD¹
(MILLIONS)



10.3M women use non-prescription contraceptives

Non-Rx methods: barrier methods; withdrawal; periodic abstinence; tracking; other

13.0M women use no contraceptive at all

20.0M women use prescription contraceptives

Rx hormonal oral contraceptives, rings, patches, shots and IUDs/copper IUD

* Study predates commercial availability of Phexxi

\$8.3B
Contraceptive Market
(U.S. 2022)²



1. Daniels-K-and-Abma-J.-Current-Contraceptive-Status-Among-Women-Aged-15-49_NCHS-Data-Brief-Number-388-October-2020.pdf (evofem.com)

2. Grandview Research. U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product (Pills, Intrauterine Devices (IUD), Condoms, Vaginal Ring, Subdermal Implants, Injectable), And Segment Forecasts, 2022 – 2030.

EVOFEM IS LEADING THE REVOLUTION

Innovative women's reproductive and sexual health solutions



THE FIRST AND ONLY ON-DEMAND, NON-HORMONAL PRESCRIPTION CONTRACEPTIVE VAGINAL GEL

- Vaginal pH Modulator
- Hormone-free
- FDA-approved for prevention of pregnancy
- Woman-controlled
- Used only when you need it
- Box of 12 Phexxi applicators

phexxi®




MARCH 27, 2024

MOA - PHEXXI IS A pH MODULATOR



Optimal vaginal pH levels can range from 3.5 – 4.5



When semen (pH 7.1-8) enters the vagina, it raises the environmental pH level

Allows sperm to be mobile and swim up the reproductive canal


Phexxi keeps vaginal pH in the optimal range

Among subjects who used Phexxi in the registrational clinical trials, only 1.6% discontinued due to an adverse reaction.

This is lower than published rates of hormonal methods, which range from 9.6% to 20.1% discontinuation due to adverse reactions



EVERY 1% MARKET SHARE OF THE 43.3M WOMEN IN OUR ADDRESSABLE MARKET REPRESENTS SIGNIFICANT NET PRODUCT SALES



1. Effective January 1, 2024. WAC: Wholesale Acquisition Cost.


MARCH 27, 2024

2. Annual net sales calculation: Net \$ to EVFM per box * boxes/year/women * 433,000 women (1% of 43.3M women in Phexxi addressable market)

NET PRODUCT SALES GROWTH SINCE LAUNCH



Three consecutive years of revenue growth




MARCH 27, 2024

NET PRODUCT SALES NOW EXCEED SALES & MARKETING COST



Quarterly selling and marketing expense as a percent of net product sales



MARCH 27, 2024

ACTIVATING SELECT PATIENT TYPES TO USE PHEXXI



- Targeting women who are aligned with the current Phexxi user profiles
- Capitalizing on where Phexxi is already performing

PHEXXI PATIENT AGE

- The majority of Phexxi patients are within the 25-39 age range¹
- Average age of Phexxi user is 33 years old

NOT USING A PRESCRIPTION
CONTRACEPTIVE

LIVING WITH
DEPRESSION AND ANXIETY

POSTPARTUM MOTHER

STRUGGLES WITH HER WEIGHT

IN NEED OF NON-SYSTEMIC
CONTRACEPTION

CANCER SURVIVOR

WANTS NON-HORMONAL


1. IQVIA Phexxi claims data, July 2022

ACTIVATING PHEXXI UTILIZATION WITH SELECT PATIENT TYPES



phexxi[®]
(lactic acid, citric acid, and potassium bitartrate) Vaginal Gel
1.8%, 1%, 0.4%

Prior Contraception Among Women Switching to Phexxi¹



WE ARE SUCCESSFULLY REACHING OUR TARGET PATIENT TYPES


1. IQVIA Phexxi claims data, July 2022

CREATING THE VAGINAL PH MODULATOR CATEGORY



Changing the contraceptive counseling conversation to make it personal


HORMONE FREE



VAGINAL pH MODULATOR


- A vaginal gel that keeps the vagina in the normal acidic range (3.5-4.5), which lowers sperm mobility and the chance of sperm reaching the egg
- Inserted into the vagina immediately before (or up to 1 hour before) each act of vaginal sex

used in the moment




CONDOM

- A barrier that covers the penis or vagina during sex
- Protects against HIV, other STIs, and pregnancy




SPERMICIDE

- A cream or film that contains the chemical nonoxonyl-9 to prevent pregnancy
- Inserted into the vagina before vaginal sex




FERTILITY TRACKING

- The tracking of a woman's menstrual cycle and/or other fertility signs such as temperature and vaginal discharge
- Vaginal sex is avoided on days that are likely to be most fertile



COPPER IUD

- A device placed in the uterus by a healthcare professional
- Approved for up to 10 years of use




TUBAL LIGATION (getting "tubes tied")

- Sterilization surgery that is usually permanent
- For women who are sure they don't want a future pregnancy

BIRTH CONTROL IS PERSONAL. WHICH METHOD* MEETS YOUR NEEDS?


CONTAINS HORMONES

daily use




ORAL CONTRACEPTION (the "Pill")

- A pill containing hormones that prevent pregnancy
- Taken every day at the same time




PATCH

- A stick-on patch that releases hormones through the skin
- Replace once a week for 3 weeks; remove for 1 week




RING

- A flexible ring that contains hormones and is inserted into the vagina by the woman
- Insert for 3 weeks; remove for 1 week




INJECTION

- An injection of hormones by a healthcare professional
- Injection required every 3 months



HORMONAL IUD

- A device placed in the uterus by a healthcare professional
- Approved for up to 3 to 7 years of use




IMPLANT

- A small silicone rod inserted under the skin on the inside of the upper arm by a healthcare professional
- Approved for up to 3 years of use

INDICATION
Phexxi® (lactic acid, citric acid, and potassium bitartrate) is an on-demand method of birth control used to prevent pregnancy. Phexxi is not effective when used after sex.

IMPORTANT SAFETY INFORMATION
Rare cases (0.36%) of bladder and kidney infection have been reported. If you have a history of urinary tract problems that keep coming back, you should not use Phexxi.

Please see additional Important Safety Information on back and accompanying Full Product Information for Phexxi.



HORMONE FREE

BIRTH CONTROL IS PERSONAL.

CONTAINS HORMONES

used in the moment

VAGINAL pH MODULATOR

- A vaginal gel that keeps the vagina in the normal acidic range (3.5 - 4.5), which lowers sperm mobility and the chance of sperm reaching the egg
- Inserted into the vagina immediately before (or up to 1 hour before) each act of vaginal sex

CONDOM

- A barrier that covers the penis or vagina during sex
- Protects against HIV, other STIs, and pregnancy

SPERMICIDE

- A cream or film that contains the chemical nonoxonyl-9 to prevent pregnancy
- Inserted into the vagina before vaginal sex

Semi-permanent or permanent

FERTILITY TRACKING

- The tracking of a woman's menstrual cycle and/or other fertility signs such as temperature and vaginal discharge
- Vaginal sex is avoided on days that are likely to be most fertile

COPPER IUD

- A device placed in the uterus by a healthcare professional
- Approved for up to 10 years of use

TUBAL LIGATION (getting "tubes tied")

- Sterilization surgery that is usually permanent
- For women who are sure they don't want a future pregnancy

Routine use and/or care

ORAL CONTRACEPTION (the "Pill")

- A pill containing hormones that prevent pregnancy
- Taken every day at the same time

PATCH

- A stick-on patch that releases hormones through the skin
- Replace once a week for 3 weeks; remove for 1 week

RING

- A flexible ring that contains hormones and is inserted into the vagina by the woman
- Insert for 3 weeks; remove for 1 week

INJECTION

- An injection of hormones by a healthcare professional
- Injection required every 3 months

Semi-permanent or permanent

HORMONAL IUD

- A device placed in the uterus by a healthcare professional
- Approved for up to 3 to 7 years of use

IMPLANT

- A small silicone rod inserted under the skin on the inside of the upper arm by a healthcare professional
- Approved for up to 3 years of use

WHICH METHOD* MEETS YOUR NEEDS?

Use this chart to help determine which methods might be right for you. Talk to your doctor about what you want in your birth control.

*Products are not shown at actual size.

INDICATION
Phexxi® (lactic acid, citric acid, and potassium bitartrate) is an on-demand method of birth control used to prevent pregnancy. Phexxi is not effective when used after sex.

IMPORTANT SAFETY INFORMATION
Rare cases (0.36%) of bladder and kidney infection have been reported. If you have a history of urinary tract problems that keep coming back, you should not use Phexxi. Contact your healthcare provider if you are experiencing genitourinary side effects such as vaginal burning, itching, discharge, genital discomfort (including in male partners), yeast infection, urinary tract infection or bacterial vaginosis.

IMPORTANT SAFETY INFORMATION
Phexxi does not protect against any sexually transmitted infections, including HIV. Avoid using Phexxi with a vaginal ring. Avoid Phexxi if you or your sexual partner is allergic to lactic acid, citric acid, potassium bitartrate, or any of the ingredients in Phexxi. Stop using Phexxi if you develop an allergic reaction.

For more information about Phexxi, talk to your healthcare provider and see full Product Information. Please report side effects by contacting EvoFem Biosciences® toll-free at 1-833-EVMBIO or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

EVOFEM BIOSCIENCES® Phexxi is a registered trademark of EvoFem Biosciences, Inc. Trademark, registered or otherwise, are the property of their respective owners. © 2022 EvoFem Biosciences, Inc. - EVFM-US-001985 - June 2022 - Produced in USA.

MARCH 27, 2024

THE GLP-1 OPPORTUNITY



Glucagon-like peptide-1 (GLP-1) agonists include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)

1. Help lower blood sugar levels to treat type 2 diabetes (T2D)
 - Currently used by around 10-12% of T2D patients in the U.S.¹
2. Suppress appetite and reduce calorie intake, fueling their growing popularity as obesity drugs
 - Nearly 1 in 3 adults (30.7%) are overweight¹
 - More than 2 in 5 adults (42.4%) have obesity¹
 - About 1 in 11 adults (9.2%) have severe obesity¹

~2 million people in the U.S. were taking semaglutide medications in 2021²

JP Morgan analysts forecast that by 2030 in the U.S. alone:

- ~15 million obese patients will be on GLP-1s¹
- Around 9% of the population - 30 million people in the U.S. – may be on GLP-1s¹

¹ Schott C. *The increase in appetite for obesity drugs*. JP Morgan, November 29, 2023. <https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs>
2017–2018 data from the National Health and Nutrition Examination Survey (NHANES)

² DeSilver. *As obesity rates rise in the U.S. and worldwide, new weight-loss drugs surge in popularity*. Pew Research, March 21, 2024. <https://www.pewresearch.org/short-reads/2024/03/21/as-obesity-rates-rise-in-the-us-and-worldwide-new-weight-loss-drugs-surge-in-popularity/>

³ JP Morgan and IQVIA as cited by Reuters. <https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-sees-2024-profit-above-estimates-strong-demand-weight-loss-drug-2024-02-06/>



- **GLP-1 receptor agonists may make oral birth control pills less effective at certain points in dosing schedule**


Mounjaro and Zepbound (tirzepatide) clearly instruct HCPs to “advise females using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.”¹

- **Package inserts for semaglutide and tirzepatide products warn of potential risks to the fetus from exposure to these drugs during pregnancy**
- **Critical need for a non-systemic, non-hormonal method, like Phexxi, to provide added protection against unintended pregnancy in these patients**

¹ Zepbound Prescribing Information. <https://uspl.lilly.com/zepbound/zepbound.html#pi>

² Based on Section 8.1, *Use in Specific Populations: PREGNANCY* in the PI for semaglutide and tirzepatide products

\$224.56 MILLION NEAR-TERM GLP-1 U.S. OPPORTUNITY



1. Schott C. *The increase in appetite for obesity drugs*. JP Morgan, November 29, 2023. <https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs>
 2. Calculated based on 2022 population data from March of Dimes PeriStats <https://www.marchofdimes.org/peristats/data?top=14&lev=1&stop=129®=99&obj=9&slev=1>
 3. Daniels-K-and-Abma-J.-*Current Contraceptive Status Among Women Aged 15-49*_NCHS-Data-Brief-Number-388-October-2020.pdf (evofem.com)

LEVERAGING THE OTC OPILL OPPORTUNITY




- The progestin-only oral contraceptive Opill became available over-the-counter (OTC) in March 2024
- Opill must be taken within the same 3-hour window each day¹
- Opill users are instructed to use a barrier method for added protection every time they have sex for the next 2 days (48 hours):¹
 - after starting their first pack of Opill
 - if they take a tablet more than 3 hours late or miss a tablet on 1 or more days;
 - if they vomit or have a severe diarrhea within 4 hours of taking a tablet.
- Phexxi is a logical choice for supplemental protection against unintended pregnancy in women using Opill because it is **hormone-free**
non-systemic
on-demand
woman-controlled



¹ Opill package insert.

PHEXXI SALES COVERAGE



INCREASING PHEXXI ACCESS



- More than 82% of Phexxi claims are now being approved¹
- YTD 2023 Evofem has gained Phexxi coverage for more than 21.3M new lives¹
- We have 73% coverage within our Commercial and Medicaid books of business¹
 - 19.2M lives covered at no out-of-pocket cost¹
- Co-pay card utilization has decreased 24% since Jan. 1, 2023, while claims have remained stable

Improvements in
Phexxi coverage

Lower out-of-pocket
costs to patients

Fewer Phexxi users
need to use co-pay card

U.S. INTELLECTUAL PROPERTY PROTECTS PHEXXI INTO AT LEAST 2033



Four Orange Book listed patents

11,337,989

Method of use patent covering contraception using the L-Lactic Acid Phexxi formulation

Expected to provide protection into at least March 2033

11,439,610

Composition of matter patent covering compositions containing L-Lactic Acid, including the Phexxi formulation

Expected to provide protection into at least March 2033

10,568,855

Method of use patent covering contraception using the L-Lactic Acid Phexxi formulation

Expected to provide protection into at least March 2033

6,706,276

Composition of matter patent covering Phexxi

Currently expected to expire in March 2025

MARCH 27, 2024

WHY EVOFEM? WHY NOW?



Shattering The Hormone Glass Ceiling With First-in-class Product

Hormone-free FDA-approved contraceptive that is woman-controlled and used only when needed

Intellectual Property protection into at least 2033



Attractive Target Market

A small percentage of market share yields large revenue
Ex US license opportunities

Robust birth control industry tailwinds

MARCH 27, 2024



THANK YOU

